Why the study?
Does anticoagulation improve outcomes in patients with pulmonary arterial hypertension?
Does anticoagulation improve outcomes in patients with pulmonary arterial hypertension?
The use of anticoagulation in pulmonary arterial hypertension remains controversial due to conflicting observational data and a lack of robust randomized trials.
The use of anticoagulation as part of the treatment regimen in pulmonary arterial hypertension (PAH) remains a topic of debate. A recently published analysis of anticoagulation use in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) study offers conflicting conclusions regarding the benefit of this therapeutic strategy. There remains no robust randomized trial in PAH weighing the risks versus benefits of including anticoagulation in treatment regimens, leaving clinicians to surmise value in individual patients. Reexamination of available data may help to provide guidance on this controversial topic in the absence of future dedicated investigations.
No takes yet. Share an insight, caveat, or question.
Cirulis et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: